Terminal / Weight Loss

Cagrilintide

Phase 3

aka AM833

Long-acting amylin analog, usually run alongside semaglutide as CagriSema.

Mechanism

An amylin receptor agonist that drives satiety and slows gastric emptying, a different lever than GLP-1. Stack it with semaglutide (that combo is CagriSema) and the two mechanisms add up.

Regulatory & Safety Status

Investigational (Novo Nordisk), late-stage trials. Not approved yet.

Research

2026American heart journal

Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)

2026Diabetes, metabolic syndrome and obesity : targets and therapy

Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review

2026Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

2026Diabetes therapy : research, treatment and education of diabetes and related disorders

New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus

2024PubMed

Latest cagrilintide research

Related Compounds

Weight Loss

Semaglutide

Approved

Approved GLP-1 agonist. The drug that kicked off the whole weight-loss gold rush.

Weight Loss

Retatrutide

Phase 3

Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.